Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer

Figures & data

Figure 1 Occurrence of CTCs.

Note: Red bars indicate the CTC-positive patients; blue bars indicate the CTC-negative patients.
Abbreviation: CTC, circulating tumor cell.

Table 1 Patient characteristics

Characteristics of enrolled patients	Overall	Group A	Group B
	N=42	n=14	n=28
Median age, years	65	63	66
Median PSA values at diagnosis
≤10 ng/mL	34	9	25
>10 ng/mL	8	5	3
Gleason grade
<8	26	6	20
≥8	16	8	8
Primary treatment
Radical prostatectomy	13	5	8
Radiotherapy	14	5	9
Both	15	4	11
LH-RH therapy	18	9	9
Mean PSA values at recurrence, ng/mL	4.3	6.2	3.3
Site of recurrence
Biochemical failure	7	1	6
Prostate	14	5	9
Nodal	6	0	6
Bone + nodal	3	1	2
Bone only	12	7	5

Notes: Group A: CTC-positive patients. Group B: CTC-negative patients.

Abbreviations: CTC, circulating tumor cell; LH-RH, luteinizing hormone-releasing hormone; PSA, prostate-specific antigen.

Table 2 Numerical variables according to group differences

Variables	Group A	Group B	P-value
Median age, years (range)	63 (45–84)	66 (44–86)	0.7
Median time to first recurrence, months (95% CI)	32 (18–42)	40 (12–72)	0.6
Mean PSA values at recurrence, ng/mL (range)	6.2 (0.2–18.6)	3.3 (0.2–15.8)	0.5

Notes: Group A: CTC-positive patients. Group B: CTC-negative patients.

Abbreviations: CTC, circulating tumor cell; PSA, prostate-specific antigen.

Table 3 Categorical variables according to group differences

Variable	Categories	Group A, n (%)	Group B, n (%)	P-value
Primary treatment	Radical prostatectomy	5 (35.7)	8 (28.5)	0.25
	Radiotherapy	5 (35.7)	9 (32.1)
	Both	4 (28.5)	11 (39.2)
Sites of recurrence	Bone	8 (57.1)	7 (25)	0.04
	Non-bone	6 (42.8)	21 (75)
Gleason score	<8	6 (42.8)	20 (71.4)	0.07
	≥8	8 (57.1)	8 (28.5)

Notes: Group A: CTC-positive patients. Group B: CTC-negative patients. Statistically significant value is shown in bold.

Abbreviation: CTC, circulating tumor cell.